Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
Top Page
Japan Tissue Engineering Co., Ltd.
(7774)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥600.00
▲(4.35% Upside)
Action:ReiteratedDate:03/31/26
The score is primarily constrained by inconsistent profitability and negative cash flow despite strong revenue growth and an excellent, low-debt balance sheet. Technicals are mixed (below short-term averages but not overbought/oversold), while valuation is weak due to loss-making results and no dividend support.
Positive Factors
Low-debt balance sheet
A near-zero debt profile provides durable financial flexibility to fund R&D, scale manufacturing and absorb periodic cash burn without heavy interest burden. This reduces solvency risk and supports longer-term investment in regulatory and commercial milestones.
Negative Factors
Negative operating cash flow
Recurring negative operating and free cash flow indicates the business is not yet self-funding; it increases reliance on external capital despite low debt. Over months this raises dilution and funding-risk sensitivity if revenue or margins falter during scale-up phases.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-debt balance sheet
A near-zero debt profile provides durable financial flexibility to fund R&D, scale manufacturing and absorb periodic cash burn without heavy interest burden. This reduces solvency risk and supports longer-term investment in regulatory and commercial milestones.
Read all positive factors
Japan Tissue Engineering Co., Ltd. (7774) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥25.42B
Dividend YieldN/A
Average Volume (3M)51.90K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-5.65%
EPS Growth-469.19%
CountryJP
Employees211
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model
Company Description
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers auto...
How the Company Makes Money
Japan Tissue Engineering makes money primarily by commercializing regenerative medicine products and related manufacturing/services. Key revenue streams include: (1) Product sales: revenue generated from selling approved regenerative medicine prod...
Japan Tissue Engineering Co., Ltd. Financial Statement Overview
Summary
Income Statement
47
Neutral
Balance Sheet
82
Very Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.44B | 2.46B | 2.51B | 2.03B | 2.10B | 2.26B |
| Gross Profit | 1.48B | 1.47B | 1.67B | 1.12B | 1.24B | 1.14B |
| EBITDA | -130.55M | -124.74M | 242.31M | -596.67M | -373.21M | -363.97M |
| Net Income | -286.56M | -255.30M | 143.17M | -729.32M | -497.89M | -466.62M |
Balance Sheet | ||||||
| Total Assets | 6.29B | 6.51B | 6.99B | 6.88B | 7.60B | 8.12B |
| Cash, Cash Equivalents and Short-Term Investments | 3.92B | 3.89B | 4.27B | 4.13B | 4.93B | 5.28B |
| Total Debt | 0.00 | 0.00 | 0.00 | 133.00K | 936.00K | 1.74M |
| Total Liabilities | 710.70M | 687.95M | 908.43M | 946.15M | 931.66M | 954.78M |
| Stockholders Equity | 5.58B | 5.83B | 6.08B | 5.94B | 6.67B | 7.16B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -224.48M | 78.23M | -771.66M | -327.82M | -461.80M |
| Operating Cash Flow | 0.00 | -148.37M | 274.14M | -622.60M | -225.25M | -399.59M |
| Investing Cash Flow | 0.00 | -232.53M | -242.23M | 1.12B | -116.48M | 125.89M |
| Financing Cash Flow | 0.00 | -3.00K | -134.00K | -803.00K | -823.00K | -1.30M |
Japan Tissue Engineering Co., Ltd. Technical Analysis
Neutral
575.00
Price Trends
631.38
Negative
567.06
Positive
555.26
Positive
Market Momentum
-12.11
Positive
45.49
Neutral
8.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Neutral. The current price of 575 is below the 20-day moving average (MA) of 639.35, below the 50-day MA of 631.38, and above the 200-day MA of 555.26, indicating a neutral trend. The MACD of -12.11 indicates Positive momentum. The RSI at 45.49 is Neutral, neither overbought nor oversold. The STOCH value of 8.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7774.
Japan Tissue Engineering Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥17.31B | 120.78 | ― | ― | 1.24% | -33.41% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥25.42B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥51.57B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.66B | -8.14 | ― | ― | -42.49% | -2.37% | |
43 Neutral | ¥164.65B | -35.18 | -253.07% | ― | ― | -12.69% |
* Healthcare Sector Average
JP:7774
Japan Tissue Engineering Co., Ltd.
626.00
222.00
54.95%
JP:4592
SanBio Co
2,110.00
564.00
36.48%
JP:4593
Healios KK
382.00
158.00
70.54%
JP:4974
Takara Bio Inc.
1,141.00
417.00
57.60%
JP:4978
ReproCELL Inc.
182.00
57.00
45.60%
JP:7776
CellSeed Inc.
300.00
-247.00
-45.16%
Japan Tissue Engineering Co., Ltd. Corporate Events
Japan Tissue Engineering Widens Loss and Cuts Sales Outlook for Fiscal 2025
Jan 30, 2026
Japan Tissue Engineering reported non-consolidated results for the nine months to 31 December 2025 showing an 11.5% year-on-year decline in net sales to ¥1.51 billion and a deeper operating loss of ¥563 million, with net loss widening to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.